Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (May 2022)

27 slides from Windtree Therapeutics's investor presentation, May 23, 2022

  1. Slide 1: Early Cardiogenic Shock Investor Call

    Windtree Therapeutics Early Cardiogenic Shock Investor Call Ma 2022 WINDTREE THERAPEUTICS VINT)

  2. Slide 2: Forward-Looking Statements

    St ooking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company's cli

  3. Slide 3: Istaroxime Early Cardiogenic Shock Update

    Istaroxime Early Cardiogenic Shock Update: Istaroxime early cardiogenic shock data from our SEISMiC Phase 2 study was presented at a late- breaker session earlier today here at the ESC Heart Failure meeting: “The safety and efficacy of istaroxime for PreCardiogenic Shock” Speaker: Marco Metra, MD (U

  4. Slide 4: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart ual Mechan of Action m =... Inhibition of the sodium- eoiaven cy erhceeece enhances calcium reuptake resulting in potassium pumpandeffectson IStarOxXime im

  5. Slide 5: Istaroxime AHF Phase 2a & 2b Studies — Summary

    Istaroxime AHF Phase 2a & 2b Studies —- Summary Multicenter, double blind, placebo-controlled, parallel group in 240 patients Phase 2a Phase 2b = © n=120 Dosing= 6 hour ADHF Patients 0.5, 1, 1.5 g/kg /min Infusion n=120 Dosing= 24 hour ADHF Patients 0.5, 1.0 ug/ke/min Infusion (dyspnea plus need for

  6. Slide 6: Acute Heart Failure Phase 2b

    Acute Heart Failure Phase 2b Significant Improvements in E/e', Stroke Volume and Blood Pressure along with a Favorable Renal Profile , . E/e’ Systolic Blood Pressure (SBP) 20 2 10 00 a 3° a £2 B., fo 7 59 Infusion pe ga | + 60 a * prvalues < 0.0: 5 *pvele=0011,%* ovale 004 Baseline — Shours — 24hour

  7. Slide 7: SEISMIC Study

    SEISMIC Study Istaroxime in Early Cardiogenic Shock Additional potential indication in active clinical development SR windTREE ae

  8. Slide 8: Cardiogenic Shock

    Cardiogenic Shock Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output > Caused by severe impairment of cardiac function that results in diminished cardiac output, end-organ hypoperf

  9. Slide 9: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need > No satisfactory pharmacological intervention to reverse the conditions * Availabletherapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal dysfunction and

  10. Slide 10: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Pathway FDA Regulatory Commentary and Precedent Sponsors are potentially not required to show benefit other than an increase in blood pressure to support approval of drugs to treat hypotension in the setting of shock)

  11. Slide 11: SEISMIC Early Cardiogenic Shock Study

    SEISMIC Early Cardiogenic Shock Study Early cardiogenic shock study: Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure = 60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF > Study drug was infused for 24 hours in a 1:1 randomiza

  12. Slide 12: SEISMIC Results Summary

    SEISMIC Results Summary SEISMIC was a positive study in early cardiogenic shock patients = Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025) = Key secondary endpoints

  13. Slide 13: Primary Endpoint — Difference in SBP Profile

    Primary Endpoint — Difference in SBP Profile Systolic Blood Pressure AUC through 6 Hours - mITT Population mit Bistaroxime is §Placebo Bio Change from Baseline in 0 5 1 1S 2 25 3 35 4 #45 5 SS 6 Hours from Infusion Inititation S windTREE ae

  14. Slide 14: Secondary Results — Systolic BP Improvements Persisted over 24 Hours

    Secondary Results - Systolic BP Improvements Persisted over 24 Hours Systolic Blood Pressure mITT Population Change in SBP (mmHg) 2 Py Hours from Infusion Inititation —e-lIstaroxime --«- Placebo ER €2 WINDTREE

  15. Slide 15: Cardiac Function Improvement

    Cardiac Function Improvement Echocardiography demonstrated improvements in key systolic and diastolic cardiac function measures including: ¢ Cardiac index significantly increased ¢ Stroke volume substantially increased and approached statistical significance © Other echocardiographic measurements si

  16. Slide 16: Treatment was Associated with a Positive Renal Profile

    Treatment was Associated with a Positive Renal Profile €2 WINDTREE Renal function was not decreased with istaroxime infusion Istaroxime treated patients also had greater diuresis with less cumulative diuretic use Estimated Glomerular Filtration Rate miTT Population oS ‘Change From Baclino in oGFR y

  17. Slide 17: Serious Adverse Events and Adverse Drug Reactions

    Serious Adverse Events and Adverse Drug Reactions Istaroxime (N=29) Alladverse events 27 (93%) 25 (81%) Serious adverse events 6 (21%) 6 (19%) Cardiac arrest 1(3%) 0) Cardiac failure 2 (7%) 2 (6%) Cardiac failure acute 0 1(3%) Cardiac ventricular thrombosis 0 1 (3%) Cardiac artery stenosis 0 1 (3%)

  18. Slide 18: Comparison of Doses

    Comparison of Doses 1.0 ug/kg/min Produced a Favorable Effect on SBP Change from Baseline in SBP (mmHg) Hours from Infusion Initiation 21.0 ug/ke/min —e—1.5 ug/ke/min -e -Placebo | SQwinorree Al Subjects(n=60) .

  19. Slide 19: Safety and Efficacy Appeared more Favorable with the 1.0 vs 1.5 µg/kg/min and Placebo

    Safety and Efficacy Appeared more Favorable with the 1.0 vs 1.5 yg/kg/min and Placebo 1.0 ug/kg/min dosing was associated with: * Attractive early SBP increase and improvement in more echocardiographic parameters of cardiac function * More favorable adverse event, serious adverse event and clinical

  20. Slide 20: SEISMIC Results Summary

    SEISMIC Results Summary SEISMIC was a positive study in early cardiogenic shock patients = Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025) oO SBP increases were rap

  21. Slide 21: SEISMIC Trial — Relevance to the Acute Heart Failure (AHF) Program

    SEISMIC Trial — Relevance to the Acute Heart Failure (AHF) Program = The early cardiogenic shock trial results are consistent with Windtree’s Phase 2 AHF studies and complementary to further advancement in AHF. = While SEISMIC was an early cardiogenic shock study, the patients studied had very sever

  22. Slide 22: Cardiogenic Shock Development Strategy

    Cardiogenic Shock Development Strategy SEISMIC Study = Proof of Concept = SCAI Stage B due to AHF = Learnings about dosing and effect, etc. DTREE SEISMIC Extension Study — * Optimize the dosing = Additional characterization of effect SCAI Stage C Study = Gain experience in SCAI stage C patients — *

  23. Slide 23: SEISMIC Extension Study (amendment to the ECS study)

    SEISMIC Extension Study (amendment to the ECS study) Following the positive results in the early cardiogenic shock study, an extension study is planned to support ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology

  24. Slide 24: Planned SCAI Stage C Cardiogenic Shock Patient Study

    Planned SCAI Stage C Cardiogenic Shock Patient Study While a smaller group than SCAI stage B, given positive results in early cardiogenic shock, the strategy is to gain experience in more severe, SCAI stage C patients to support both regulatory, development and commercial strategies Study objectives

  25. Slide 25: Strategy for Value Creation

    Strategy for Value Creation Istaroxime Cardiogenic Shock © ‘Meet w/FDA; EMA Re Phase 2 SEISMIC Extension Study 9 (SEISMic) " EEE Results SCAI Stage C Study Istaroxime Acute Heart Failure Study _~18 months to execute; E0P2 Mtg A eee ralare (transition to Phase 3)** Into Ph3, potential partnering “4 O

  26. Slide 26: Summary — Potential to Create Value

    Summary - Potential to Create Value = Istaroxime has been successfully studied in 7 clinical trials (3 being Phase 2 trials) with approximately 300 patients treated with istaroxime to date (and plans to grow) = Istaroxime has positive Phase 2a and 2b results demonstrating: v Improved cardiac functio

  27. Slide 27: Windtree Therapeutics

    Windtree Therapeutics SR windTREE oe

Windtree Therapeutics — Investor Presentation (May 2022) on 6ix